Denali Therapeutics Inc.
DNLI
$19.00
$1.166.50%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -100.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -100.00% |
| Cost of Revenue | 2.01% | 3.24% | 23.81% | 13.45% | 26.55% |
| Gross Profit | -2.01% | -3.57% | -1,157.64% | -1,996.01% | -2,856.21% |
| SG&A Expenses | 26.98% | 16.02% | 7.99% | 2.02% | -1.91% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.89% | 5.79% | 0.74% | -6.21% | 0.43% |
| Operating Income | -6.89% | -6.06% | -138.48% | -145.30% | -202.41% |
| Income Before Tax | -16.66% | -14.14% | -230.78% | -191.13% | -243.52% |
| Income Tax Expenses | 126.67% | 126.67% | 126.67% | 126.67% | 600.00% |
| Earnings from Continuing Operations | -16.67% | -14.15% | -230.75% | -191.12% | -243.56% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.67% | -14.15% | -230.75% | -191.12% | -243.56% |
| EBIT | -6.89% | -6.06% | -138.48% | -145.30% | -202.41% |
| EBITDA | -6.46% | -5.91% | -144.94% | -163.60% | -234.12% |
| EPS Basic | -5.30% | 1.62% | -187.36% | -144.79% | -197.15% |
| Normalized Basic EPS | 3.51% | 9.49% | -119.64% | -121.42% | -204.45% |
| EPS Diluted | -5.30% | 1.62% | -176.04% | -136.24% | -185.46% |
| Normalized Diluted EPS | 3.51% | 9.49% | -113.32% | -115.11% | -193.75% |
| Average Basic Shares Outstanding | 9.46% | 14.83% | 20.85% | 19.71% | 15.04% |
| Average Diluted Shares Outstanding | 9.46% | 14.83% | 20.02% | 18.87% | 14.23% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |